EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study

Isabel Leroux-Roels, Cathy Maes, Francesca Mancini, Bart Jacobs, Eleanna Sarakinou, Azhar Alhatemi, Jasper Joye, Silvia Grappi, Giulia Luna Cilio, Alimamy Serry-Bangura, Claudia G Vitali, Pietro Ferruzzi und 14 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae273 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Isabel Leroux-Roels und 25 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium. Hauptthemen laut MEDLINE: Shigella Vaccines, Antibodies, Bacterial, Shigella sonnei, Shigella flexneri. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline Biologicals, Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We report data from stage 1 of an ongoing 2-staged, phase 1/2 randomized clinical trial with a 4-component generalized modules for membrane antigens-based vaccine against Shigella sonnei and Shigella flexneri 1b, 2a, and 3a (altSonflex1-2-3; GSK).

Methods

Europeans aged 18–50 years (N = 102) were randomized (2:1) to receive 2 injections of altSonflex1-2-3 or placebo at 3- or 6-month interval. Safety and immunogenicity were assessed at prespecified time points.

Results

The most common solicited administration-site event (until 7 days after each injection) and unsolicited adverse event (until 28 days after each injection) were pain (altSonflex1-2-3, 97.1%; placebo, 58.8%) and headache (32.4%; 23.5%), respectively. All serotype-specific functional IgG antibodies peaked 14–28 days after injection 1 and remained substantially higher than prevaccination at 3 or 6 months postvaccination; the second injection did not boost but restored the initial immune response. The highest seroresponse rates (≥4-fold increase in titers over baseline) were obtained against S. flexneri 2a (enzyme-linked immunosorbent assay [ELISA] after injection 1, 91.0%; after injection 2 [day 113; day 197], 100%; 97.0% and serum bactericidal activity [SBA] after injection 1, 94.4%; after injection 2, 85.7%; 88.9%) followed by S. sonnei (ELISA after injection 1, 77.6%; after injection 2, 84.6%; 78.8% and SBA after injection 1, 83.3%; after injection 2, 71.4%; 88.9%). Immune responses against S. flexneri 1b and S. flexneri 3a, as measured by both ELISA and SBA, were numerically lower compared to those against S. sonnei and S. flexneri 2a.

Conclusions

No safety signals or concerns were identified. altSonflex1-2-3 induced functional serotype-specific immune responses, allowing further clinical development in the target population. Clinical Trials Registration . NCT05073003.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Shigella VaccinesAntibodies, BacterialShigella sonneiShigella flexneriDysentery, BacillaryImmunoglobulin GHumansAdultMaleFemaleMiddle AgedYoung AdultAdolescentEuropeAntigens, BacterialImmunogenicity, VaccineHealthy Volunteers

Stichwörter der Autor:innen

Shigella vaccineO-antigenaltSonflex1-2-3immunogenicitysafety

Substanzen

Shigella VaccinesAntibodies, BacterialImmunoglobulin GAntigens, Bacterial

Autor:innen und Institutionen

  • Center for Vaccinology, Ghent University and Ghent University Hospital, Ghent, Belgium.
  • GSK Vaccines Institute for Global Health, GSK, Siena, Italy.
  • VisMederi, Siena, Italy.
  • Vaccines Global Safety, GSK, Siena, Italy.
  • Vaccines Toxicology Center of Excellence, GSK Siena, Italy.
  • GSK Biologicals, Siena, Italy.

ORCID-Profile: Usman N Nakakana

Förderung

  • GlaxoSmithKline Biologicals
  • Bill and Melinda Gates Foundation

Zitieren

APA

Leroux-Roels, I., Maes, C., Mancini, F., Jacobs, B., Sarakinou, E., Alhatemi, A., Joye, J., Grappi, S., Cilio, G. L., Serry-Bangura, A., Vitali, C. G., Ferruzzi, P., Marchetti, E., Necchi, F., Rappuoli, R., De Ryck, I., Auerbach, J., Colucci, A. M., Rossi, O., …, & Shigella Project Team (2024). Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae273

Vancouver

Leroux-Roels I, Maes C, Mancini F, Jacobs B, Sarakinou E, Alhatemi A, et al. Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae273

BibTeX
@article{LerouxRoels2024,
  author = {Leroux-Roels, Isabel and Maes, Cathy and Mancini, Francesca and Jacobs, Bart and Sarakinou, Eleanna and Alhatemi, Azhar and Joye, Jasper and Grappi, Silvia and Cilio, Giulia Luna and Serry-Bangura, Alimamy and Vitali, Claudia G and Ferruzzi, Pietro and Marchetti, Elisa and Necchi, Francesca and Rappuoli, Rino and De Ryck, Iris and Auerbach, Jochen and Colucci, Anna M and Rossi, Omar and Conti, Valentino and Scorza, Francesco Berlanda and Arora, Ashwani Kumar and Micoli, Francesca and Podda, Audino and Nakakana, Usman N and Shigella Project Team, Shigella Project Team},
  title = {Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae273}
}
Kostenlos starten →